title: Insulin resistance and decreased glucose-stimulated insulin secretion after acute olanzapine administration.
abstract: The newer atypical antipsychotics, as a class, have been associated with an increased risk of weight gain and metabolic abnormalities. The mechanisms underlying this phenomenon are currently unclear, but there are data to suggest the possibility of an immediate (as opposed to chronic) effect of these drugs. The aim of the present study was to assess the acute effects of olanzapine on specific measures of insulin sensitivity and secretion. Healthy animals were tested in either the hyperinsulinemic-euglycemic or the hyperglycemic clamp. After reaching steady state in the hyperinsulinemic-euglycemic clamp, rats were injected with olanzapine (3 mg/kg sc) and monitored for an additional 130 minutes. In the hyperglycemic clamp, olanzapine was injected approximately 90 minutes before receiving a glucose bolus, and hyperglycemia was maintained via exogenous glucose infusion for an additional 90 minutes. Insulin and C-peptide levels were monitored throughout this clamp.Acute administration of olanzapine significantly lowered the glucose infusion rate due to an increase in hepatic glucose production and a decrease in glucose utilization. Olanzapine pretreatment induced hyperglycemia and markedly decreased plasma insulin and C-peptide in response to the glucose challenge. These findings indicate that olanzapine can directly induce metabolic changes that occur rapidly and well in advance of the changes that might be anticipated as a result of its weight-gain liability. We present novel findings highlighting an olanzapine-induced deficit in beta-cell functioning.
authors.affiliation: Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada.
authors.forename: Araba F
authors.initials: AF
authors.lastname: Chintoh
authors.forename: Steve W
authors.initials: SW
authors.lastname: Mann
authors.forename: Loretta
authors.initials: L
authors.lastname: Lam
authors.forename: Carol
authors.initials: C
authors.lastname: Lam
authors.forename: Tony A
authors.initials: TA
authors.lastname: Cohn
authors.forename: Paul J
authors.initials: PJ
authors.lastname: Fletcher
authors.forename: Jose N
authors.initials: JN
authors.lastname: Nobrega
authors.forename: Adria
authors.initials: A
authors.lastname: Giacca
authors.forename: Gary
authors.initials: G
authors.lastname: Remington
mesh_terms: D000818:Animals; D014150:Antipsychotic Agents / Q000009:adverse effects*; D001569:Benzodiazepines / Q000009:adverse effects*; D002096:C-Peptide / Q000187:drug effects / Q000378:metabolism; D004195:Disease Models, Animal; D005947:Glucose / Q000378:metabolism; D015309:Glucose Clamp Technique; D006943:Hyperglycemia / Q000139:chemically induced / Q000378:metabolism; D007328:Insulin / Q000378:metabolism*; D007333:Insulin Resistance; D000078790:Insulin Secretion; D050417:Insulin-Secreting Cells / Q000187:drug effects / Q000378:metabolism; D008297:Male; D000077152:Olanzapine; D051381:Rats; D017207:Rats, Sprague-Dawley; D013997:Time Factors
chemical_list: D014150:Antipsychotic Agents; D002096:C-Peptide; D007328:Insulin; D001569:Benzodiazepines; D005947:Glucose; D000077152:Olanzapine